Connect Biopharma Holdings (CNTB) Capital Expenditures (2024 - 2026)
Connect Biopharma Holdings (CNTB) posted Capital Expenditures of -$2000.0 for Q1 2026, down 101.07% sequentially from $187000.0 in Q4 2025, and down 102.47% YoY from $81000.0 in Q1 2025.
Connect Biopharma Holdings (CNTB) Capital Expenditures (2024 - 2026) Analysis & Trends
Connect Biopharma Holdings has reported Capital Expenditures for 3 years, with the latest figure at -$2000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 102.47% year-over-year to -$2000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $522000.0 (down 37.11% YoY) and the FY2025 annual result came in at $605000.0, down 19.33% from the prior year.
- Capital Expenditures eased to -$2000.0 in Q1 2026 per CNTB's latest filing, from $187000.0 in the prior quarter.
- Over five years, Capital Expenditures peaked at $313000.0 in Q4 2024 and troughed at -$2000.0 in Q1 2026.
- A 3-year average of $150333.3 and a median of $147000.0 in 2024 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2025 and 2026: Capital Expenditures soared 8000.0% in 2025, then plunged 102.47% in 2026.
- Over 3 years, Capital Expenditures stood at $313000.0 in 2024, then sank by 40.26% to $187000.0 in 2025, then slumped by 101.07% to -$2000.0 in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered -$2000.0, $187000.0, and $34000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Connect Biopharma Holdings | 148.41 Mn | 148.41 Mn | - | -1,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,000.00 |
| Jun 30, 2026 | -1,000.00 |
| Mar 31, 2026 | -2,000.00 |
| Mar 31, 2026 | -2,000.00 |
| Dec 31, 2025 | 187,000.00 |
| Dec 31, 2025 | 187,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 303,000.00 |
| Jun 30, 2025 | 303,000.00 |
| Mar 31, 2025 | 81,000.00 |
| Mar 31, 2025 | 81,000.00 |
| Dec 31, 2024 | 313,000.00 |
| Dec 31, 2024 | 313,000.00 |
| Sep 30, 2024 | 147,000.00 |
| Sep 30, 2024 | 147,000.00 |
| Jun 30, 2024 | 289,000.00 |
| Jun 30, 2024 | 289,000.00 |
| Mar 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 1,000.00 |